GoldenGolden
Advanced Search
Foresite Capital

Foresite Capital

A private equity firm in California that provides catalytic capital to transformative healthcare companies at all stages

Foresite Capital is a private equity firm in California that provides catalytic capital to transformative healthcare companies at all stages. Founded 2011 in San Francisco, California, United States by Jim Tananbaum, this private equity firm invests in private equity, early stage ventures and late stage ventures. Its portfolio companies include Genapsys, Aimmune Therapeutics, Generation Bio, Element Biosciences, and Kinnate Biopharma. As of February 2020, Foresite Capital has made 66 investments. Their most recent investment was on Jan 11, 2020, when Generation Bio raised $110M. Foresite Capital has had 27 exits. Foresite Capital's most notable exits include Aimmune Therapeutics, Twist Bioscience, and Alector. The company has raised 4 funds, their latest being Foresite Capital Fund IV. This fund was announced on May 3, 2018 and raised a total of $668M. The company prefers to invest in the healthcare, therapeutics, devices, diagnostics and services sectors.

Timeline

February 23, 2021
Foresite Capital banks $969 million in its fifth and biggest raise yet to invest in companies solving some of the biggest inefficiencies in today's healthcare system.
2011
Founded

Invested in

Associated investment funds

Patents

Products

Funding Rounds Participated In

People

Name
Role
LinkedIn

Dorothy Margolskee

Managing Director

Brett Zbar

Managing Director

Jim Tananbaum

Founding CEO

Linda Schaffer

Director

Molly He

Venture Partner

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

Pharvaris

Element Biosciences

Genapsys

Generation Bio

HealthVerity

News

Title
Author
Date
Publisher
Description
Amirah Al Idrus
June 29, 2021
FierceBiotech
Foresite Capital's second special purpose acquisition company (SPAC) has landed on its target: Pardes Biosciences, a biotech working on antiviral treatments for COVID-19. Through the merger, Pardes will add about $276 million to the bank, which will get its lead candidate into the clinic later this year.
Brandon May
May 14, 2021
BioSpace
Foresite Labs-incubated company Interline Therapeutics announced Thursday that it had raised $92 million in a financing round co-led by Foresite Capital and ARCH Venture Partners.
Aetion
May 11, 2021
www.prnewswire.com:443
/PRNewswire/ -- Health care technology company Aetion announced today a $110 million Series C fundraise, led by Warburg Pincus, a leading global growth equity...
Annalee Armstrong
April 13, 2021
FierceBiotech
Theseus Pharmaceuticals, led by a team of ex-Ariad executives, will target treatment-resistant cancers after emerging from stealth mode with $100 million in Series B funding.
FinSMEs
April 13, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
SHOW MORE

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.